{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McLean RK"],"funding":["Biotechnology and Biological Sciences Research Council,United Kingdom","Innovate UK,United Kingdom","Biotechnology and Biological Sciences Research Council"],"pagination":["163"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12287429"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(1)"],"pubmed_abstract":["Nipah virus (NiV) causes a severe neurological disease in humans. The first NiV outbreak, in Malaysia, involved pig-to-human transmission, that resulted in significant economic losses to the local pig industry. Despite the risk NiV poses to pig-dense regions, no licensed vaccines exist. This study therefore assessed three NiV vaccine candidates in pigs: (1) adjuvanted soluble NiV (s)G protein, (2) adjuvanted pre-fusion stabilised NiV (mcs)F protein, and (3) adenoviral vectored NiV G (ChAdOx1 NiV G). NiV sG induced the strongest neutralising antibody response, NiV mcsF induced antibodies best able to neutralise cell-cell fusion, whereas ChAdOx1 NiV G elicited CD8<sup>+</sup> T-cell responses. Despite differences in immunogenicity, prime-boost immunisation with all candidates conferred a hig"],"journal":["NPJ vaccines"],"pubmed_title":["Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health."],"pmcid":["PMC12287429"],"funding_grant_id":["971555","BBS/E/I/00007039","BBS/E/I/00007031"],"pubmed_authors":["Thakur N","Watterson D","Bailey D","Marsh GA","Hodgson S","Gilbert SC","Pedrera M","Rowe B","Begum MN","Reid T","Isaacs A","Bruce M","Trinidad L","Lowther S","Bergfeld J","Bhuyan AAM","Graham SP","Lambe T","Edwards S","Rahman MZ","Au G","Barr J","Chappell K","Tchilian E","Layton R","Raue R","Todd S","Mourino M","Rahman M","Alam M","Rye N","Young P","Shanta IS","Siddika A","Elrefaey AME","Fisher M","Poole T","Rahman S","McLean RK","Payne J","Riddell S","Brown S","Dalziel T"],"additional_accession":[]},"is_claimable":false,"name":"Nipah virus vaccines evaluated in pigs as a 'One Health' approach to protect public health.","description":"Nipah virus (NiV) causes a severe neurological disease in humans. The first NiV outbreak, in Malaysia, involved pig-to-human transmission, that resulted in significant economic losses to the local pig industry. Despite the risk NiV poses to pig-dense regions, no licensed vaccines exist. This study therefore assessed three NiV vaccine candidates in pigs: (1) adjuvanted soluble NiV (s)G protein, (2) adjuvanted pre-fusion stabilised NiV (mcs)F protein, and (3) adenoviral vectored NiV G (ChAdOx1 NiV G). NiV sG induced the strongest neutralising antibody response, NiV mcsF induced antibodies best able to neutralise cell-cell fusion, whereas ChAdOx1 NiV G elicited CD8<sup>+</sup> T-cell responses. Despite differences in immunogenicity, prime-boost immunisation with all candidates conferred a hig","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-07-15T14:14:25.802Z","creation":"2025-08-17T03:05:54.049Z"},"accession":"S-EPMC12287429","cross_references":{"pubmed":["40702012"],"doi":["10.1038/s41541-025-01212-y"]}}